Johnson & Johnson MedTech innovates at the intersection of biology and technology. With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex health challenges. Healthcare areas include: Cardiovascular, Orthopaedics ...
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.
NEW BRUNSWICK, N.J.-- (BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. “2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Last year kicked off a new era of accelerated growth, driven by ...
Working with Johnson & Johnson isn’t just any job. It’s an invitation to align your career with transformational breakthroughs in health. Because we’re driven by a passion to achieve the best version of health for everyone, everywhere—and existing barriers aren’t going to break themselves.
Explore Johnson & Johnson's corporate information, financial updates, and investor resources on this comprehensive platform.
NEW BRUNSWICK, N.J.-- (BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “The depth and strength of our portfolio and pipeline is unrivaled and ...